30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Sleep disturbances are pervasive in Lewy body disorders (LBD), but their neurophysiological basis remains unclear. 1 key finding →
Participants: 109 Evidence: low
Full summary, score breakdown and related studies → Original source
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. 3 key findings →
Design: meta-analysis Participants: 213,604 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings implicate significant liver–brain crosstalk through which chronic alcohol exposure may modulate AD-relevant pathology and reinforce the growing recognition of the liver as a critical organ in AD pathogenesis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia. 5 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
When stable individual differences are accounted for, depressive symptoms emerge as a stronger within-person temporal predictor of cognitive decline than physical activity. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the English Longitudinal Study of Ageing (ELSA: n=9,473, median age 64, range 50 to ≥90), linear mixed-effects models examined age-specific differences in cognitive change (recall and fluency) associated with sleep duration, difficulty falling asleep, nocturnal awakenings, incorporating sleep-by-age-by-time interactions, with initial adjustment for sociodemographic factors and further adjustment for health and lifestyle factors. 5 key findings →
Design: cohort study Participants: 9,473 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Participants were aged 60–94 years, with a mean age of 78.5 ± 7.9 years, and 45.7% were women. 5 key findings →
Design: cross-sectional Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Sleep disturbance in Alzheimer’s disease (AD), particularly the reduction of slow wave sleep (SWS), has been proposed as a novel therapeutic target, with disease-modifying potential. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleeping more than one’s usual average the night before testing was associated with better delayed memory ( β = 0.03, p = 0.02), while no between-person sleep effects emerged. 5 key findings →
Design: cross-sectional Participants: 329 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Traumatic brain injuries (TBIs) are associated with increased risk of neurodegenerative disease, including Alzheimer’s disease (AD); however, the mechanisms by which TBI promotes AD pathogenesis remain poorly understood. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disruption is common in Alzheimer’s disease (AD). 1 key finding →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
DORA-22 and MK-1064 rescued tauopathy-related sleep loss, and reduced agitation-like locomotion and stress-induced hyperthermic responses. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Seasonally normalized 25(OH)D identifies a reproducible state of systemic vulnerability while reducing exposure misclassification caused by calendar timing of measurement. 5 key findings →
Design: longitudinal study Participants: 412,020 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We estimated associations per SD slower walking or smaller adaptability using linear, logistic, and Cox regression (10-year follow-up), overall and in women and men. 5 key findings →
Design: cross-sectional Participants: 2,308 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A key pathophysiological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is loss of nuclear localization and abnormal cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Middle East and North Africa (MENA) region represents the area of greatest projected growth in instances of Alzheimer’s disease and related dementias (ADRDs) globally, yet, it remains virtually uncharacterized in health studies of aging and ADRDs. 4 key findings →
Participants: 3,552 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
Central Nervous System (CNS) hyperexcitability is increased during aging and also during alcohol withdrawal. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Electronic health records linked documented glucosamine use to faster progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) and poorer survival after dementia. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
INTRODUCTIONLittle is understood about the extent to which lifestyle factors can advance or delay the risk of developing dementia, and whether that is dependent on non-modifiable factors, e.g. sex and genetic susceptibility.METHODSAmong 224,516 UK Biobank participants aged ≥50 years at baseline, Cox regression examined the relations of apolipoprotein E gene (APOE) genotypes, and lifestyle with incident dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
DMII provides a metabolomics-based framework for assessing diet-related chronic inflammation using metabolomics data. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings provide evidence that age-related changes in the gut microbiota, particularly reductions in Bifidobacterium , partially mediate cognitive decline in older adults. 5 key findings →
Design: cross-sectional Participants: 578 Evidence: low
Full summary, score breakdown and related studies → Original source
Physical exercise promotes systemic and neural adaptations that support healthy brain aging and may mitigate Alzheimer’s disease (AD) progression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Passive sleep monitoring identified physiologically interpretable sleep markers associated with next-day agitation occurrence, supporting prospective evaluation of under-mattress sensing as a source of short-term risk information for dementia care. 4 key findings →
Participants: 55 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Evidence for interventions that reduce refusal is strongest for music during personal care and modified bathing methods, with some support for positive communication and person-centred approaches, though quality is generally low and few studies involve family caregivers in community settings. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,021 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events